Trials / Terminated
TerminatedNCT01948180
Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma
A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Cell Medica Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive EBV positive extranodal NK/T-cell lymphoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | baltaleucel-T | Autologous EBV-specific T-cells |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2018-04-16
- Completion
- 2018-09-07
- First posted
- 2013-09-23
- Last updated
- 2019-03-13
Locations
11 sites across 4 countries: United States, France, South Korea, United Kingdom
Source: ClinicalTrials.gov record NCT01948180. Inclusion in this directory is not an endorsement.